Female players must undergo genetic testing to play on tennis tour

The Women’s Tennis Association (WTA) has introduced mandatory genetic sex testing for players wishing to compete in its tour.

The new policy, which comes into effect today, will require any players wanting to participate in WTA events to undergo a one-time test via a cheek swab, blood test, or saliva sample.

The test checks for the presence of the SRY gene, part of the Y chromosome and essential for being male. If a player tests positive for SRY they will need to go through further medical tests before they might be allowed to participate. Players will also need to sign an agreement that they will face disciplinary action if they refuse to take a test.

WTA events include Wimbledon, Roland Garros, and The United States and Australian Opens.

This new policy brings the WTA in line with the International Olympic Committee (IOC), World Athletics, and other sports governing bodies in requiring female competitors to prove their sex. World Athletics’ policy came into effect last year, and the IOC’s new rules will take effect for the Los Angeles games in 2028.

The WTA said: “The WTA’s women’s eligibility policy is designed to promote equal athletic opportunities in women’s professional tennis and maintain fair competition for all players participating in WTA tournaments.”

“This policy distinguishes between biological sex and gender identity, and between biological females and biological males, solely to the extent necessary to ensure that the policy is clear and has its intended effect. There is no intent to disrespect or question the gender identity or the dignity of any person.”